Frost Radar: AI-Enabled Drug Discovery, 2025

Healthcare Frost Radar: AI-Enabled Drug Discovery, 2025

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare

RELEASE DATE
12-Dec-2025
REGION
Global
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
DB62-01-00-00-00
SKU
HC_2025_34186
Yes
SHARE
$4,950.00
In stock
SKU
HC_2025_34186

Frost Radar: AI-Enabled Drug Discovery, 2025
Published on: 12-Dec-2025 | SKU: HC_2025_34186

Need more details?
$4,950.00
Need more details?

The discovery of new drug targets for diseases with unmet medical needs has long been hindered by the complexity of processing and interpreting massive volumes of biological data. The increasing volume and veracity of clinical and research data compels the use of enabling tools and technologies, such as cloud computing, AI, machine learning, natural language processing, and advanced analytics, to make the shift from the slow, traditional approach to drug discovery and development to one that is relatively fast, rational, and data-driven. To remain competitive, industry players need to establish the right balance of data, AI, and computational capability and match it with the wet lab capability. With drug discovery being primarily about understanding biological networks and drug-target interactions, AI has been seamlessly integrating itself to allow identification and prioritization of disease-specific unmet therapeutic targets. Vendor/pharmaceutical industry partnerships continue to grow, with a focus on discovery of novel compounds for treatments related to oncology, neurological conditions, aging, and rare diseases. Most established companies have successful clinical-stage molecules either in co-development/licensing agreements with pharma or developed in-house.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.

Absci Corp, US

Evaxion A/S, Denmark

Generate:Biomedicines, US

Healx, UK

Iambic Therapeutics, Inc., US

Insilico Medicine, US

Lantern Pharma, US

Peptilogics, Inc., US

Recursion Pharmaceuticals, US

Schrödinger, Inc., US

Significance of Being on the Frost Radar

CEO’s Growth Team

Investors

Customers

Board of Directors

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

04 Aug 2026   |   Global   |   Market Research

Global Capnography Devices Market, Forecast to 2031

The capnography market is undergoing a significant transformation from its traditional role in anesthesia and intensive care monitoring to a broader, continuous respiratory surveillance ecosystem. This evolution is being driven by increasing integration of capnography into multiparameter monitoring ...

31 Jul 2026   |   Global   |   Market Research

Growth Opportunities in Small-Molecule Contract Development and Manufacturing Organizations, Global, 2026–2031

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward s...

30 Jul 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Wearables and Drug Delivery Solutions

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, wearables and drug delivery solutions.

The issue features advanced medical devices such as non-invasive bimoda...

30 Jul 2026   |   Global   |   Frost Radar

Frost Radar™: Life Sciences Regulatory Information Management Platforms, 2026

The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical devi...

24 Jul 2026   |   Global   |   Frost Radar

Frost Radar™: Neuromodulation Devices, 2026

Neuromodulation is increasingly recognized as an effective method for managing chronic conditions and improving patients’ quality of life, gaining momentum as a cost-efficient, long-term treatment for neurological and nerve-related disorders. The prevalence of neurological disorders and nerve inju...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The discovery of new drug targets for diseases with unmet medical needs has long been hindered by the complexity of processing and interpreting massive volumes of biological data. The increasing volume and veracity of clinical and research data compels the use of enabling tools and technologies, such as cloud computing, AI, machine learning, natural language processing, and advanced analytics, to make the shift from the slow, traditional approach to drug discovery and development to one that is relatively fast, rational, and data-driven. To remain competitive, industry players need to establish the right balance of data, AI, and computational capability and match it with the wet lab capability. With drug discovery being primarily about understanding biological networks and drug-target interactions, AI has been seamlessly integrating itself to allow identification and prioritization of disease-specific unmet therapeutic targets. Vendor/pharmaceutical industry partnerships continue to grow, with a focus on discovery of novel compounds for treatments related to oncology, neurological conditions, aging, and rare diseases. Most established companies have successful clinical-stage molecules either in co-development/licensing agreements with pharma or developed in-house.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.
More Information
Deliverable Type Frost Radar
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 AI drug discovery market
Keyword 2 pharmaceutical AI platforms
Keyword 3 drug development analytics
Podcast No
Predecessor MG76-01-00-00-00
WIP Number DB62-01-00-00-00